The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Mon, 09th Dec 2019 11:23

(Alliance News) - Open Orphan PLC and hVIVO PLC on Monday said they have agreed terms on a reverse takeover, which would value the latter at GBP13.0 million.

Under the terms of the agreement, hVIVO shareholders will receive 2.47 new Open Orphan shares per hVIVO share. The deal values hVIVO shares at 15.56 pence each, a 34% premium to the clinical development services company's closing price of 11.62p on Friday.

hVIVO shares were trading 3.2% higher at 12.00p each in London on Monday morning. Drug consulting firm Open Orphan, also listed in London, was 13% lower at 5.00p each.

As the tie-up is deemed a reverse acquisition, Open Orphan needs the approval of its shareholders at a January 6 general meeting to confirm the deal.

Open Orphan said it expects to issue 205.5 million shares under the terms of the merger, with hVIVO shareholders owning just shy of 45% of the enlarged firm.

Open Orphan said: "Open Orphan and hVIVO are AIM-quoted groups that share a similar vision for the future of European Clinical Research Organisations and an entrepreneurial approach to developing further their business through a focus on operational efficiency, organic growth and targeted acquisitions to expand their geographic and service capabilities.

"The Open Orphan directors and the hVIVO directors believe that the combination of the businesses will result in synergies across the enlarged group with each business providing complementary services with limited overlap in existing capabilities and customers."

hVIVO's directors, which have backed the offer, hold a 0.3% stake in the company. Open Orphan shareholders, with an interest totalling roughly 30% of the firm, have also supported the tie-up.

Open Orphan Chief Executive Cathal Friel said: "The merger of Open Orphan and hVIVO is a key milestone in the execution of our strategy to become a larger-scale specialist pharma services business and in complementary segments where specialist skills and know-how command higher margins.

"The merger allows the combined business to maximise shareholder value through delivering cost and revenue synergies across the businesses and one that is better positioned to consistently capture greater market share as part of a properly profitable business with losses confined to the past."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
15 Nov 2021 11:32

Open Orphan subsidiary secures contract renewal with 'major' pharmaceutical client

(Sharecast News) - Contract research organisation Open Orphan said on Monday that its Venn Life Sciences subsidiary had signed a contract renewal with an unnamed "major global pharmaceutical client" worth £1.5m over a two-year period.

Read more
13 Oct 2021 13:25

EXECUTIVE CHANGES: Halfords hires CFO; new Pendragon, Versarien chairs

EXECUTIVE CHANGES: Halfords hires CFO; new Pendragon, Versarien chairs

Read more
20 Sep 2021 14:30

Open Orphan signs £5.7m contract with biotech specialist

(Sharecast News) - Clinical research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a £5.7m contract with a specialist biotechnology company developing therapeutics for respiratory viral infections, to test its antiviral product using the hVIVO Influenza human challenge study model.

Read more
20 Sep 2021 12:02

TRADING UPDATES: Christie Group and Open Orphan swing to profit

TRADING UPDATES: Christie Group and Open Orphan swing to profit

Read more
13 Sep 2021 16:11

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
7 Sep 2021 18:16

TRADING UPDATES: Victoria growth continues; Renew to beat consensus

TRADING UPDATES: Victoria growth continues; Renew to beat consensus

Read more
7 Sep 2021 14:59

TRADING UPDATES: Marlowe buys Santia; Gaming Realms notes new launch

TRADING UPDATES: Marlowe buys Santia; Gaming Realms notes new launch

Read more
24 Aug 2021 11:41

AIM WINNERS & LOSERS: Open Orphan rises on asthma study contract win

AIM WINNERS & LOSERS: Open Orphan rises on asthma study contract win

Read more
24 Aug 2021 09:31

Open Orphan shares lift on GBP8.1 million asthma study contract win

Open Orphan shares lift on GBP8.1 million asthma study contract win

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
22 Jul 2021 10:49

AIM WINNERS & LOSERS: Restore rises as it rebuffs Marlowe approach

AIM WINNERS & LOSERS: Restore rises as it rebuffs Marlowe approach

Read more
14 Jul 2021 16:15

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
14 Jul 2021 15:07

IN BRIEF: Open Orphan study grows, spinoff worth GBP50 million at IPO

IN BRIEF: Open Orphan study grows, spinoff worth GBP50 million at IPO

Read more
14 Jul 2021 15:01

IN BRIEF: Open Orphan team invests GBP350,000 as spin-off set to debut

IN BRIEF: Open Orphan team invests GBP350,000 as spin-off set to debut

Read more
14 Jul 2021 09:10

Open Orphan secures €900,000 contract with existing customer

(Sharecast News) - Pharmaceutical services company Open Orphan has secured a new contract win with an unnamed existing customer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.